Literature DB >> 9513885

Medical management of congenital portosystemic shunts in 27 dogs--a retrospective study.

P J Watson1, M E Herrtage.   

Abstract

Case records of 27 dogs with medically managed congenital portosystemic shunts were reviewed. Fourteen were followed up by telephone questionnaires to the owners. Age, breed, sex, clinical signs and blood results were similar to previous studies. Weight and quality of life were stable or improved on treatment in all cases. Total serum protein concentration and alanine aminotransferase and alkaline phosphatase activities fell significantly during treatment. Fourteen dogs were euthanased, four were lost to follow-up and nine remained alive. Mean survival time for the dogs euthanased was 9.9 months. Mean follow-up period for the dogs still alive was 56.9 months and all had survived more than 36 months from diagnosis. Surviving dogs with intrahepatic shunts had a significantly shorter follow-up period than dogs with extrahepatic shunts. Two prognostic indicators were identified, age at initial signs and blood urea concentration on presentation, both correlating with survival time. It was demonstrated that a significant proportion of dogs with portosystemic shunts managed medically have a good prognosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9513885     DOI: 10.1111/j.1748-5827.1998.tb03595.x

Source DB:  PubMed          Journal:  J Small Anim Pract        ISSN: 0022-4510            Impact factor:   1.522


  7 in total

1.  Splenophrenic portosystemic shunt in dogs with and without portal hypertension: can acquired and congenital porto-caval connections coexist?

Authors:  M Ricciardi
Journal:  Open Vet J       Date:  2016-11-05

Review 2.  Treatment of congenital extrahepatic portosystemic shunts in dogs: A systematic review and meta-analysis.

Authors:  Gonçalo Serrano; Marios Charalambous; Nausikaa Devriendt; Hilde de Rooster; Femke Mortier; Dominique Paepe
Journal:  J Vet Intern Med       Date:  2019-08-31       Impact factor: 3.333

3.  Astrocyte lesions in cerebral cortex and cerebellum of dogs with congenital ortosystemic shunting.

Authors:  Alun Williams; Adam Gow; Scott Kilpatrick; Mickey Tivers; Vicky Lipscomb; Ken Smith; Michael Oliver Day; Nick Jeffery; Richard John Mellanby
Journal:  J Vet Sci       Date:  2020-05       Impact factor: 1.672

4.  Comparison of diet, lactulose, and metronidazole combinations in the control of pre-surgical clinical signs in dogs with congenital extrahepatic portosystemic shunts.

Authors:  Goncalo Serrano; Nausikaa Devriendt; Hilde de Rooster; Dominique Paepe
Journal:  J Vet Intern Med       Date:  2022-05-28       Impact factor: 3.175

5.  Characterization of the Fecal Microbiome in Dogs Receiving Medical Management for Congenital Portosystemic Shunts.

Authors:  Nathan Squire; Cassie Lux; Katie Tolbert; Jonathan Lidbury; Xiaocun Sun; Jan S Suchodolski
Journal:  Front Vet Sci       Date:  2022-07-28

6.  Genome-wide based model predicting recovery from portosystemic shunting after liver shunt attenuation in dogs.

Authors:  Lindsay Van den Bossche; Frank G van Steenbeek; Maarten F Weber; Bart Spee; Louis C Penning; Freek J van Sluijs; Flin Zomerdijk; Marian J A Groot Koerkamp; Jan Rothuizen; Iwan A Burgener; Anne Kummeling
Journal:  J Vet Intern Med       Date:  2018-05-17       Impact factor: 3.333

7.  Outcome of non-surgical dietary treatment with or without lactulose in dogs with congenital portosystemic shunts.

Authors:  Robert P Favier; Eline de Graaf; Ronald J Corbee; Anne Kummeling
Journal:  Vet Q       Date:  2020-12       Impact factor: 3.320

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.